Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602420 · ClinicalTrials.gov registry record · Phase 3
Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)
A Phase 3 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
NCT00602420 is a Phase 3 study that has completed, run by Gary Morrow. The registered enrollment target is 510 participants.
The verdict
NCT00602420, a Phase 3 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
Study Summary
RATIONALE: Naproxen may help prevent or lessen bone pain caused by pegfilgrastim. It is not yet known whether naproxen is more effective than a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy. PURPOSE: This randomized phase III trial is studying naproxen to see how well it works compared with a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy.
Interventions
- OTHER placebo
- DRUG naproxen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00602420
The ClinicalTrials.gov registry entry for NCT00602420 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00602420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00602420 about?
NCT00602420 is a clinical study titled "Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)". RATIONALE: Naproxen may help prevent or lessen bone pain caused by pegfilgrastim. It is not yet known whether naproxen is more effective than a placebo in preventing bone pain caused by pegfilgrastim in patients with non-hematologic cancer undergoing chemotherapy. PURPOSE: This randomized phase III...
What is the current status of trial NCT00602420?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2008-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00602420?
The interventions under investigation include: placebo (OTHER), naproxen (DRUG).
Who is sponsoring clinical trial NCT00602420?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.